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Phenylguanine Found in Urine
after Benzene Exposure
K.H. Norpoth, G. Muller, C. Schell, and E. Jorg
Institute of Hygiene and Occupational Medicine, University Medical
Center, Essen, Germany
Comparative investigations with synthetic N7-phenylguanine were carried out to clarify whether
this compound is eliminated via the urine of rats as a benzene-derived nucleic acid adduct. As
sensitive methods for detecting trace amounts of the compound, gas chromatography-mass
spectroscopy, high performance liquid chromatography, and two immunoassays (enzyme-linked
immunosorbent assay and fluoroimmunoassay) with appropriate monoclonal antibodies were
used. The results indicate the excretion of several benzene-related guanine adducts slightly
different from N7-phenylguanine that may possibly be hydroxylated. These adducts
differ also from o6-, N2- and C8-phenylguanine, respectively. Environ Health Perspect
104(Suppl 6):1159-1163 (1996)
Key words: DNA adducts, benzene, N7-phenylguanine, urine, 14C, HPLC, GC-MS,
monoclonal antibodies
Introduction
There is ample evidence that benzene
uptake by mammalians leads to the
formation of nucleic acid adducts after
biotransformation ofthe carcinogen (1-13).
Identification of (3'OH)benzetheno-
(N1,N2)-deoxyguanosine as a DNA adduct
by Jowa et al. (3,14) was confirmed by
Snyder et al. (4) and Kaur et al. (5).
Following the hypothesis that
N7-phenylguanine could be formed by the
reaction of benzene epoxide with guanine
(Figure 1), attempts were undertaken in
our laboratorv to identify it as an in vivo
adduct after administering single, high
doses of benzene to male Wistar rats ip.
Having in mind that well known N7-gua-
nine adducts of aflatoxin B1 (15) and
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benzo[a]pyrene (16) are excreted in the
urine, our investigations focused on urine
analyses. We were aware ofthe limitations
ofsuch an approach. No decision is possi-
ble as to whether guanine derivatives are
generated by arylation of DNA, RNA, or
free guanine. Furthermore, the amounts
excreted should reflect water solubility of
the adduct rather than production rates.
Highly sensitive and specific methods are
required for the urine analyses. On the
other hand, ifN7-phenylguanine is formed,
it should be eliminated from DNA very
rapidly because beside excision repair
mechanisms, it will depurinate and may
accumulate in body fluids.
UrineAnalyses Using CationExchange
Chromatography, HPLC, and GCMS
After having synthesized N7-phenyl-
guanine (17), we analyzed urine samples in
comparison investigations, methods for
which are reported by Norpoth et al. (18).
In Figure 2 the separation of urine
components after exposure with cation
exchange chromatography (UV detection)
0 + Guanine - o
is presented in comparison to the spectra of
the control urine and of the control urine
containing the synthetic N7-phenylgua-
nine. One of the peaks (32 min) exhibits
the same retention time and, after separa-
tion, an identical fluorometric behavior as
that of the synthetic N7-phenylguanine
(Figure 3). The substances that represent
the other peaks have not yet been identified.
Our hypothesis ofthe adduct formation
was further confirmed by high perfor-
mance liquid chromatography (HPLC)
measurements with reversed phase carrier
material (Figure 4). The urine fraction
containing the phenylguanine was isolated
by cation exchange chromatography and
after a clean-up with Sep Pak C18 cartridges
(Baker, Phillipsburg, NJ) this fraction was
measured by HPLC. As shown in Figure 4,
the urine ofrats treated with 50 pil benzene,
ip, in contrast to that of untreated rats,
produced several peaks. Again, one of the
peaks showed the same retention time as
the synthetic N7-phenylguanine.
To compare N7-phenylguanine with
other possible phenyl adducts present in
the urine, silylation and gas chromatogra-
phy-mass spectrometry (GC-MS) analyses
were performed. After separation with
cation exchange chromatography and
clean-up with Sep Pak C18 cartridges, the
sample was silylated and fractionated by
capillary gas chromatography. The detec-
tion was performed with a Kratos MS 80
mass spectrometer (Kratos, Manchester,
UK) (Figure 5).
Measurements revealed the retention
time ofa compound with a molecular mass
of 371 and a mass fragment of 356, as
observed with the synthetic N7-phenylgua-
nine. The data obtained suggested that
N7-phenylguanine can be detected in the
urine of rats treated with high doses of
benzene. Discussing this conclusion we
underlined that another adduct may be
formed originally; for example, a hydroxy
compound (similar to the products observed
in the metabolism of benzo[a]pyrene),
which will be transformed into the dehy-
droxylated phenylguanine during the
H
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Figure 1. Proposed scheme for the reaction of benzene epoxide with guanine.
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preparation of the urine samples. Such
behavior could also be observed in the
detection ofglutathione adducts of some
polycyclic aromatic hydrocarbons (19,20).
Investgatons with [14C]Benzene and
Unlabeled Benzene UsingaRefined
HPLCTechnique
Three male Wistar rats (average weight:
270 g) were exposed to [14C]benzene (113
mCi/mmol, purchased from Amersham
Buchler, Braunschweig, Germany (3.3
mCi respiration 13.3 ppm/hr each) in a
closed system (exsiccator, 10.3 x 10-3 m3).
The reduction of [14C]benzene in the air
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N7-phenylguanine
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Figure 2. Chromatographic separation of phenylgua-
nine in urine samples (cation exchange chromatogra-
phy/UV detection).
Excitation 300 nm
450 370 290 nm
Figure 3. Fluorescence spectra ofthe reference ( )
and the fractionated sample (-------) with the same
fluorescence maxima at 385 and 350 nm. The third
maximum detected (not marked) is attributed to the
aqueous buffer solution (. )
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Figure 4. HPLC separation (UV detection) of phenyl-
guanine in urine samples.
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Figure 5. GC-MS measurements at m/e 371 (mole-
cular mass of N7-phenylguanine) and m/e 356 (mass
fragment) with different urine samples.
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was controlled by GC measurements. After
6 hr, leaving 4 ppm benzene in the air, the
animals were transferred into individual
metabolic cages and 24-hr urine samples
were collected over 6 days. Bone marrow
(from two femura), liver, spleen, thymus,
and blood were prepared. Nuclear and
mitochondrial DNA were isolated sepa-
rately (8) with the exception ofbone mar-
row, where the DNA was not separated. In
liver, RNA and protein were also obtained
(21). Urine, urine fractions, tissue, nucleic
acid, and protein labels were measured by
liquid scintillation counting. For counting
methods, sample preparation, and HPLC
conditions, see Krewet et al. (22).
For comparison investigations four
phenylguanines were synthesized according
to the given methods: N7-phenylguanine,
multistage synthesis according to Verkoyen
et al. (17), 06-phenylguanine, synthesis
according to Balsinger and Montgomery
(23), C8-phenylguanine, multistage syn-
thesis according to Chin et al. (24,25),
N2-phenylguanine, multistage synthesis
according to Elion et al. (26,27) and
Albert et al. (28).
The analyses of urine samples from
benzene-treated animals and analyses of
hydrolyzed tissue DNA revealed, in com-
parison with the chromatograms of the
same samples containing synthesized
phenylguanines, that the detected sub-
stances were not identical to our references
(Figures 6, 7). The peak patterns from
samples of treated animals showed some
deviations compared to those of control
samples and the detected compounds had
characteristic excretion kinetics over the
examination period of 6 days. These peak
patterns were also observed with only
slight modifications in samples ofpheno-
barbital-pretreated animals. The detected
compounds were different from known
benzene metabolites.
After the urine analyses [14C]benzene
was used to decide whether the compounds
detected in rat urine samples and DNA
were benzene adducts different from the
synthesized phenylguanines. A lower detec-
tion limit (1-100 pg) was achieved and
information about the excretion kinetics
was obtained. Rats exposed to radioactive
benzene by inhalation showed the expected
marked decrease in the urinary 14C label
48 hr after the end of exposure, but these
remained unchanged from days 4 to 6
(Figure 8). Over the 6 days ofurine collec-
tion, 26.3% of the dose inhaled could be
detected. The label excreted daily in urine
samples from day 4 to day 6 was 0.6%.
Cation exchange chromatography
Urine after exposure
120 90 60
Retention time, min
Fraction C8- and N2-phenylguanine Fra
HPLC HPLC
10 15 20
Retention time, min
10 15 'A
Retention time, min
Figure 6. Chromatographic separation of a rat urine sample after exposure to benzene (500 mg/kg bw) using
cation exchange chromatography and HPLC ofcollected phenylguanine fractions
Cation exchange chromatography
Urine after exposure + phenylguanines
120 90 60
Retention time, min
Fraction C8- and N2-phenylguanine Fri
HPLC HPLC
10 15
Retention time, min
20 10 15 20
Retention time, min
Figure 7. Chromatographic separation of a rat urine sample after exposure to benzene (500 mg/kg bw) spiked with
100 ng N7- and 06-phenylguanine and 200 ng C8- and N2-phenylguanine per milliliter, injection volume 50 pl,
using cation exchange chromatography and HPLC of collected phenylguanine fractions.
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Figure 8. Excretion kinetics of labeled compounds in
24-hr urine samples of rats after exposure to 114C]ben-
zene (mean values of three rats).
The phenylguanine fractions were
further analyzed by HPLC. Twenty frac-
tions per gradient were collected and
measured by liquid-solid chromatography.
Four compounds with retention times of
10.5 to 11, 13.5, 15.5 to 16, and 18 min
were separated from the N7/06-phenyl-
guanine fraction. Their excretion was com-
pleted on day 4, with the exception ofthe
late-eluting compound (Figure 9). In the
C8/N2-phenylguanine fraction, four com-
pounds were also detected, showing reten-
tion times of 13.5, 15 to 15.5, 17 to 17.5
and 18 to 18.5 min. Their excretion was
completed on days 3 to 5 after the end of
exposure (Figure 10).
The reactivity of benzene oxide with
DNA or polyguanine was examined using
microsomes for the activation ofbenzene.
Phenylguanines were not detected during
the analysis of hydrolyzed nucleic acid
samples (DNA or polyguanine) from
microsomal incubations with benzene.
After incubation of guanine and deoxy-
guanosine with p-benzoquinone and
hydroquinone, two identical products were
found that differed from all our reference
substances in regard to their HPLC reten-
tion times. No such product was formed
in similar incubation experiments with
trans-trans-muconaldehyde.
InvestigtionswithMonoclonal
Antibodies
A definitive decision as to whether
N7-phenylguanine is present in the urine
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Figure 9. Excretion kinetics of 14C-labeled compounds
in 24-hr urine samples of rats(C8-/N2-phenylguanine).
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Figure 10. Excretion kinetics of 14C-Iabeled compounds
in 24-hr urine samples of rats (N7-/06-phenylguanine).
of benzene-treated rats was achieved by
means of enzyme-linked immunosorbent
assay (ELISA) and fluoroimmunoassay
(FIA) analyses (29). Using monoclonal
antibodies obtained against 2-hydroxy-
methyl-7-phenyl hypoxanthine (Figure 11),
N7-phenylguanine could be detected when
added to urine samples in amounts of 100
fmol with an ELISA and 50 fmol with an
FIA (Figure 12). In purified urine samples
ofbenzene-treated rats N7-phenylguanine
could not be found by applying these
highly sensitive and specific techniques.
Conclusions
As demonstrated by GC-MS, benzene is
metabolized in the rat to one or more gua-
nine adducts of unknown structure, which
can be detected in the urine.
Our study with [14C]benzene demon-
strates the occurrence of 14C-labeled
compounds in the urine ofrats exposed to
0
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Figure 11. Structure of 2-hydroxymethyl 7-phenyl-
hVDoxanthine.
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Figure 12. Competitive inhibition of mAb CE6/G11
binding to N7-phenylguanine in enzyme-linked
immunosorbent assay and fluorescent immunoassay.
[14C]benzene by inhalation, which may be
deoxyguanosine, guanine, or adenine
adducts released from arylated DNA. The
excretion of labeled compounds in urine
samples remained constant from the
4th day after exposure and measurable
radioactivity could be detected in bio-
logical macromolecules 6 days after the end
ofexposure.
As shown by highly sensitive and
specific ELISA and FIA techniques, the
phenylguanine(s) found differ also with
respect to their immunologic behavior
from N7-phenylguanine.
All our findings are in accordance with
the hypothesis that compound(s) slightly
different from N7-phenylguanine, possibly
containing a hydroxy function, are excreted
as guanine adduct(s) ofbenzene.
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